GRDX Overview

GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Wall Street analysts forecast GRDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

GridAI Technologies Corp revenue for the last quarter amounts to -935.00K USD, decreased -50.61 % YoY.

GridAI Technologies Corp. EPS for the last quarter amounts to -855688.00 USD, decreased -53.71 % YoY.

GridAI Technologies Corp (GRDX) has 2 emplpoyees as of January 26 2026.

Today GRDX has the market capitalization of 11.00M USD.